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Abstract
Bemcentinib is a newly developed AXL inhibitor that is currently under investigation in phase II trails for the treatment of acute
myeloblastic leukemia (AML). Clinical and radiographic findings in this case were very similar to cases of MRONJ in patients
receiving Sunitinib or other anti-angiogenetic substances, assuming that Bemcentinib may cause similar oral side effects. We
present a male 81-year-old patient with a manifestation of alveolar bone necrosis at the central upper incisors following a 2-month
regimen with the AXL-inhibitor Bemcentinib, administered for the treatment of secondary acute myeloblastic leukemia (sAML).
Due to the duration of less than 8 weeks, the osteonecrosis was diagnosed as necrotizing periodontitis, but the intraoral clinical
and radiographic findings were also compatible with the differential diagnosis of medication-related osteonecrosis of the jaw
(MRONJ, stage II). Following to discontinuation of Bemcentinib, the affected bone was surgically revised including the removal
of a demarcated bone sequester under preventive antibiotic treatment (metronidazole 400 mg t.i.d.). We hypothesize that
Bemcentinib might increase the susceptibility for osteonecrosis of the jaw, probably related to its antiangiogenic effects and
the resulting modulation of host immune response. Based on the current observations, it can be assumed that oro-dental health
might be significant also prior and during treatment with Bemcentinib for the prevention of MRONJ.
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Background
The idea of developing an extensive arsenal of active sub-
stances for targeted and individual cancer therapy has pro-
duced an array of anti-angiogenetic active substances, e.g.,
Sunitinib [1–4], that might induce medication-related
osteonecrosis of the jaw as a side effect. Bemcentinib (BGB
324), currently under investigation in phase II trails
(C l i n i c a lT r i a l s . gov / I d en t i f i e r : NCT03965494 ,
NCT03824080 , NCT03654833 , NCT03649321 ,
NCT03184571, NCT03184558), is targeting AXL with addi-
tional antiangiogenic effects [5]. Herein, we report a case of
medication-related osteonecrosis of the upper jaw after
Bemcentinib regimen for the treatment of secondary acute
myeloblastic leukemia. Clinical and radiographic findings
were very similar to cases of MRONJ as previously described
using Sunitinib [1–3] or other anti-angiogenetic substances [6,
7]. We show clinical findings and review the literature.
Case presentation
An 81-year-old male patient with a diagnosis of secondary
acute myeloblastic leukemia (sAML) treated with the AXL
inhibitor Bemcentinib for 2 months as part of a phase II trail
was referred to the outpatient clinic of the Department of
Conservative Dentistry and Periodontology, University
Hospital Munich due to exposed alveolar bone of the upper
anterior jaw persisting for approximately 4–5 weeks in
June 2019. Despite discontinuation of AXL inhibitor therapy
immediately upon first manifestation, the bone exposure
remained unaffected. Besides general fatigue, the patient re-
ported occasional pain in the area of exposure during masti-
cation, whereas other signs of inflammation, such as fever or
lymphadenopathy, were not observed. Secondary findings
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were atrial fibrillation, hypertension, aortic aneurysm, and
cholelithiasis. Antihypertensive therapy was conducted with
bisoprolol (1.25 mg o.d.), torasemid (10 mg o.d.), and
candesartan (8 mg o.d.). In addition, the patient received
apixaban (2.5 mg b.i.d.) for the prevention of ischemic stroke.
According to anamnesis, the patient was currently not under-
going dental treatment and no oral examination had been per-
formed prior to initiation of treatment with Bemcentinib.
Preliminary clinical or radiological dental findings were not
available. The patient did never receive radiation therapy of
the head and neck region.
Clinical examination, including a standardized dental ex-
amination, as well as a localized periodontal examination,
including the central maxillary incisors, was carried out. In
order to avoid excessive bleeding resulting from AML-
associated thrombopenia and drug-related anticoagulation, a
periodontal examination of the remaining dentition was not
conducted. However, a generalized accumulation of hard and
soft dental plaque reflected the patient’s inadequate oral hy-
giene; thus, a pre-existing periodontal disease could not be
excluded. Focusing on the maxillary anterior dentition, the
interdental gingival tissue of the central upper incisors pre-
sented with significant ulceration causing extensive exposure
of the crestal parts of the interdental bone. The margins of the
soft tissue defect showed minor swelling and redness. The
exposed bone appeared necrotic due to grey discoloration
and was mobile upon gentle probing indicating partial demar-
cation and sequestration. Both incisors showed gingival reces-
sion defects > 6 mm at the mesial aspects of the tooth root
(Fig. 1a, b). The probing pocket depth was 12 mm at the
mesio-buccal and the mesio-palatal sites. Apical radiograph
of the relevant area revealed a c-shaped radiolucent area of
5 mm in the middle third of the interdental osseous tissue
between the central incisors compatible with a zone of demar-
cation (Fig. 1i). Based on the clinical and radiographic signs
and the overall duration of only 4–5 weeks, a diagnosis of
necrotizing periodontitis (NP) with the differential diagnosis
of MRONJ (stage II) according to the AAOMS [4] and the
indication for the surgical removal of the osseous sequester
was made.
Due to the aforementioned thrombopenia (platelet 50 ×
103/μl), the patient received platelet concentrate 2 h preoper-
atively in order to improve hemostasis during the surgical
procedure and to prevent postoperative secondary bleeding.
Afterwards, the sequestrotomy was performed under local an-
esthesia (1.7 ml articain hydrochloride 4% with epinephrine
1:200,000) followed by subgingival scaling using curettes of
the adjacent root surface (Fig. 1c, d) and suturing in order to
approach wound margins and to ease coagulation.
Immediately after completion of the surgical treatment, both
central maxillary incisors presented with significantly in-
creased mobility. To prevent further impairment, temporary
splint using a resin-based composite was placed (Fig. 1e). One
day preoperatively, the patient received metronidazole
(400 mg t.i.d.) which was continued upon completion of
wound closure after 7 days. After uneventful healing, except
slight residual gingival swelling, there were no signs of in-
flammation detectable (Fig. 1f). At final clinical visit, 5-
week postoperative gingival swelling had entirely ceased
and the gingival recession increased 2 mm at both incisors
(Fig. 1g, h). Histopathological examination of the surgically
removed tissue depicted in Fig. 1j confirmed the clinical find-
ings by revealing necrotic bone with inflammatory cell infil-
trate and gram-positive, rod-shaped bacteria (Fig. 2a–d).
Discussion and conclusions
AXL receptor tyrosine kinase—effects and inhibition
Bemcentinib (BGB324) is an inhibitor of the AXL receptor
whose therapeutic effect on sAML is currently under investi-
gation in clinical phase II trials [8, 9]. The AXL receptor
tyrosine kinase is a member of the Tyro-3, AXL, and Mer
(TAM) subfamily that can be almost ubiquitously found with-
in many different tissues [5, 10–13]. Upon Gas6 activation,
AXL mediates cell proliferation and migration through Ras/
Raf/MEK/ERK and the Src signaling pathway as well as cell
survival by S6, AKT, or JNK [10, 13, 14]. Regarding the
immune system, AXL mediates efferocytosis, a reduced
TLR-dependent inflammatory response, and natural killer cell
activity [12, 14]. In the tumor immune microenvironment,
AXL is often overexpressed by dendritic cells, NK cells, or
macrophages, promoting epithelial to mesenchymal transi-
tion, tumor angiogenesis, resistance to chemotherapeutic and
targeted agents, and decreased antitumor immune response [5,
13, 15, 16]. AXL activation in dendritic cells inhibits TLR and
TLR-induced cytokine-receptor cascades [12] and reduces
dendritic cell activity as well as complement T cell checkpoint
cascade [16]. Activation of the tumor-associated macrophage
receptor AXL by Gas6 or Protein S has shown to shift mac-
rophage polarization, inducing pro-tumor m2 polarization and
inhibiting pro-inflammatory m1 polarization [11]. Several
studies confirm a TAM-related downregulation of m1 polari-
zation leading to decreased secretion of pro-inflammatory cy-
tokines such as interleukin-1 beta (IL-1β), interleukin-6 (IL-
6), and tumor necrosis factor-α (TNF-α) [17–21]. Moreover,
another study demonstrated increased expression levels of
these cytokines in Gas6 or Protein S-inhibition models [20].
On the other hand, AXL signaling increases the polarization
of m2-like macrophages. Under physiological conditions, the
m2 phenotype is involved in maintenance of tissue homeosta-
sis, consolidation of inflammatory processes, and wound
healing through efferocytosis, angiogenesis, and secretion of
anti-inflammatory cytokines [11, 14, 22, 23]. In the tumor
microenvironment, however, m2-like functions are
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overexpressed via TAM regulation, ultimately leading to tu-
mor angiogenesis [22, 24], impaired anti-tumor immunity,
tumor growth, and metastasis [23, 25].
AXL inhibitors such as Bemcentinib counteract these numer-
ous effects. By inhibiting the formerly altered macrophage po-
larization mentioned above, angiogenesis is impaired and the
previously inhibited secretion of pro-inflammatory cytokines is
increased consequently. These two effects might present a pos-
sible link to the complex pathogenesis of periodontal disease as
occurred in this case. Actually, the aforementioned cytokines IL-
1β and TNF-α are two key marker molecules in periodontitis
that are known to play a crucial role in the development and
maintenance of inflammatory tissue degradation and alveolar
bone resorption [26, 27]. Interacting synergistically, they stimu-
late the expression of the receptor activator of nuclear factor-κB
ligand (RANKL) on the surface of osteoblasts and stroma cells,
thus promoting osteoclast formation and corresponding bone loss
[28]. Additionally, the Bemcentinib-induced inhibition of angio-
genesis in conjunction with the increased inflammatory compo-
nent could favor a rapid necrotic course of periodontitis.
Diagnosis—necrotizing periodontitis or medication-
related osteonecrosis of the jaw
Necrotizing periodontal conditions as observed in the present
case are of infectious etiology and strongly associated with
impairment of the host immune system [29]. According to the
current classification for periodontal and peri-implant diseases
and conditions [29], necrotizing periodontitis (NP) is an acute
inflammatory process of the periodontium characterized by
necrosis/ulcer of the interdental papilla, gingival bleeding, pain,
and rapid bone loss [30, 31]. As the clinical findings of this case
were consistent with all these characteristics, the working diag-
nosis necrotizing periodontitis was adjusted accordingly.
However, considering the numerous aforementioned ef-
fects of Bemcentinib on signaling cascades and the associated
anti-angiogenic and ultimately pro-inflammatory effects, the
possible influence of the AXL inhibitor on the periodontal
condition herein must be taken into account when determining
a suspect diagnosis. Hence, the differential diagnosis of a
medication-related osteonecrosis of the jaw was considered.
Fig. 1 a, b Intraoral situation with exposed bone between incisors 11 and
21. c Surgically depicted sequestrum. d Situation after sequestrotomy. e, f
Intraoral situation 7-day follow-up. g, h Intraoral situation 36-day follow-
up. i X-ray of incisors 11, 21. j Surgically removed sequestrum, divided
oro-vestibularly
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According to the 2014 AAOMS position paper, MRONJ is
defined as “exposed bone or bone that can be probed through
an intraoral or extraoral fistula(e) in the maxillofacial region
that has persisted for more than eight weeks” in a patient that
has currently or previously been treated with antiresorptive or
antiangiogenic agents and shows no history of radiation ther-
apy or obvious metastasis of the jaws [4].
Herein, there has been recorded no history of radiation ther-
apy or obvious metastasis of the jaws and the AXL inhibitor
Bemcentinib clearly has antiangiogenic effects but the exposure
of jawbone did not persist for more than 8 weeks at the time of
diagnosis. Currently, there exists considerably controversy on
the AAOMS criteria and the definition as published by the
International Task Force on ONJ in 2015 [32] specifically re-
garding the diagnosis of early stages and non-exposed cases of
MRONJ that might precede clinical and radiographic evident
sequestration and/or exposure of the jawbone [33].
Accordingly, one might argue that the necrosis of the alveolar
bone as seen in the present case was already existent unper-
ceived well before being clinically noticeable for the first time.
Moreover, histological analysis of the surgically removed
bone clearly revealed colonization with gram-positive, rod-
shaped bacteria. Regarding BRONJ, the colonization of the
affected parts of the alveolar bone specifically with gram-pos-
itive, rod-shaped Actinomyces species is highly prevalent and
was thus proposed to play a central etiologic role [34]. Apart
from the microscopic analysis, bacteria have not been, how-
ever, further characterized in the present case.
Considerations and conclusion
Regarding the pathogenesis of bone necrosis associated with
MRONJ, different etiologic models have been intensively
discussed considering mainly the effects of bisphosphonates
[1, 4]. Currently, an over-suppression of bone turnover [4,
35–37] as well as the necrosis as final result of infection in
combination with attenuation of the proliferation of various
cell types which are centrally involved into the immune re-
sponse are discussed [4, 38]. Moreover, MRONJ has been
considered to result from ischemia triggered by medication-
related antiangiogenic effects [4, 36], a general toxicity of the
medication [4, 39–41], or medication-induced shifts in pH
[42]. Oversuppression of bone turnover, comparable to oste-
oclast suppression by bisphosphonates or inhibition of RANK
ligand mediated by Denosumab [1, 38, 43], is not yet known
Fig. 2 a Necrotic bone (H&E stain, 40× magnification). b Section with
inflammatory focus, neutrophils (H&E stain, 100×magnification). c
Section of necrotic bone, empty lacunae (H&E stain, 200×
magnification). d Section of rod-shaped, gram-positive bacteria (Gram
stain, 400× magnification)
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for the AXL inhibitor Bemcentinib. On the other hand, the
above mentioned hypothesis of necrosis as the result of an
underlying infection with an additional drug-related alteration
of immune response from which a MRONJ may develop [34]
seems just as conceivable as an impaired angiogenesis. In
particular with respect to the previously mentioned shift of
macrophage polarization by AXL and the assumed opposite
shift by inhibition of AXL receptor, an excessive immune
reaction induced by increased secretion of pro-inflammatory
cytokines (m1-like phenotype induced) and simultaneously
inhibited angiogenesis and efferocytosis (m2-like phenotype
induced) is a possible mechanism of osteonecrosis of the jaw.
Furthermore, cellular toxicity caused by previously adminis-
tered cytostatics might also play a role through modulation of
the immune defense mechanisms, facilitating the necrosis.
Nevertheless, it has to be emphasized that the necrosis developed
within a comparably short period after the onset of the
Bemcentinib regimen. Therefore, the AXL inhibitor might be at
least the ultimate promoting factor. Finally, a reduction of the pH
value might have been mediated through excessive inflammation
and represents another possible mechanism of necrosis [42].
Taken together, it can be concluded that an irreversible necro-
sis and exposure of parts of the alveolar bone have developed
under a short regimen of Bemcentinib in the present case consis-
tent with the commonly accepted pathogenesis of MRONJ.
Oro-dental infections, especially periodontal disease, have
been shown to significantly increase the risk for the develop-
ment of MRONJ. Based on the present clinical case, we
strongly recommend meticulous preventive dental measures
also prior and during the administration of AXL inhibitors
such as Bemcentinib.
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